| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ENvue Medical, Inc.$0.37
+0.03 (+7.75%)
Market Cap
6.15 M
EPS
-30.48
P/E Ratio
-
Value Trade
5.38 M
SEC Financials
Q1 2026Dilution Risk
Revenue
653.00 K
R&D Expenses
468.00 K
Operating CF
-4.31 M
Total Assets
39.87 M
Total Liabilities
7.86 M
Equity
32.02 M
-11.4 %
Week
-27.86 %
1 Month
-62.87 %
3 Month
-72.33 %
6 Month
-99.95 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
2.23 M
Monthly Burn
1.44 M
Runway
0 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
905.25 K
52 Week Range
0.84 - 17.40
% held by Insiders
0.14 %
% held by Institutions
3.13 %
Enterprise Value
5.10 M
Total Shares
3.70 M
Short %
4.8 %
Float Shares
3.37 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
UroShield | spinal cord injury | — | 2023-03-14 | decrease in the number of blockages and infections and an increase in catheter satisfaction Read More | NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury Evaluators concluded that UroShield has the potential to improve quality of life and reduce healt Read More | |
UroShield | spinal cord injury | — | 2023-03-14 | decrease in the number of blockages and infections and an increase in catheter satisfaction Read More | NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury Evaluators concluded that UroShield has the potential to improve quality of life and reduce healt Read More | |
UroShield | spinal cord injury | — | 2023-03-14 | decrease in the number of blockages and infections and an increase in catheter satisfaction Read More | NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury Evaluators concluded that UroShield has the potential to improve quality of life and reduce healt Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FEED
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FEED Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FEED▲ +7.7%today
ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities
ENvue Medical has successfully moved its NanoVibronix manufacturing operations from Israel to the U.S. and consolidated its R&D in Tel Aviv. This strategic shift aims to enhance operational efficiency and reduce costs. The company anticipates that these changes will support long-term growth and improve its overall cost structure.
Read more →FEEDENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center
ENvue Medical has announced the deployment of an additional ENvue Navigation Platform at a major academic medical center in North Texas. This expansion reflects the growing confidence of clinicians in the technology, which provides real-time visualization during feeding tube placement. The company aims to enhance its presence in the competitive Dallas-Fort Worth healthcare market, focusing on minimizing complications and improving patient care.
Read more →FEED▼ -8.3%on this news· ran to -19% by day 3
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
ENvue Medical has appointed Zeev Rotstein, M.D. as Chairman of the Board, along with new directors Zvi Joseph and Lior Buchman. This leadership change aims to enhance the company's navigation and AI platforms. Rotstein brings extensive health system experience, while Joseph and Buchman contribute expertise in AI governance and capital markets, respectively.
Read more →FEED▲ +12.5%on this news
ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
ENvue Medical has unveiled the ENvue Drive, a robotic-assisted tool that integrates AI and real-time navigation for feeding tube placement. This prototype aims to enhance bedside procedures by assisting clinicians while maintaining their control. The demonstration marks a significant step towards revolutionizing enteral and vascular access procedures, although the device is still investigational and not yet FDA-approved.
Read more →FEED▼ -5.3%on this news
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
ENvue Medical has launched 'Ask Oscar', an AI-powered training platform aimed at enhancing the training process for clinicians using its Navigation Platform. This innovation seeks to reduce barriers to implementation by allowing independent training and real-time feedback. The platform is expected to be commercially available soon, creating a scalable revenue opportunity for ENvue.
Read more →FEED▼ -7.9%on this news
ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
ENvue Medical will exhibit its ENvue™ Navigation Platform at the AACN NTI 2026, the largest critical care nursing conference in the U.S. The platform, which is FDA 510(k)-cleared, aids in real-time visualization during feeding tube placements. The company's participation aims to enhance clinical engagement and expand its market presence among healthcare professionals.
Read more →FEED▼ -7.5%on this news· ran to -23% by day 3
ENvue Issues Stockholder Letter & Provides Corporate Update
ENvue Medical, Inc. has issued a stockholder letter detailing its progress and future plans. The company has strengthened its leadership and expanded its technology platforms, including the ENvue Navigation Platform, now deployed in 40 hospitals. ENvue aims to address significant challenges in enteral care with innovative solutions while also expanding into home care markets. The company has secured a key patent milestone, enhancing its competitive position.
Read more →FEED▲ +58%on this news· ran to +85% by day 1
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
ENvue Medical has expanded its presence in a major Michigan health system by securing a purchase of its ENvue™ Navigation Platform and feeding tubes. This partnership increases ENvue's U.S. hospital footprint to 39. The technology aims to enhance workflow efficiency and patient safety in enteral care procedures, reflecting growing demand in the healthcare sector.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3
Clinical Specialist – Enteral Access & Navigation
The article outlines the responsibilities and qualifications for a Clinical Specialist role focused on Enteral Access and Navigation. Key tasks include training healthcare staff, onboarding new accounts, and creating educational materials. Candidates should have a relevant degree and clinical experience, particularly in enteral nutrition. The position emphasizes collaboration and patient safety.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3shared move
Junior Mechanical Engineer
The article outlines a job opportunity for a Junior Mechanical Engineer at ENvue. The role involves mechanical design, CAD modeling, and testing of medical devices. Candidates are expected to have a B.Sc. in Mechanical Engineering and experience with CAD software. The position emphasizes personal growth and contribution to safer medical solutions.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3shared move
NPI Manager
The article outlines the key responsibilities and qualifications for an NPI Manager position at ENvue, focusing on overseeing the entire NPI lifecycle for medical devices. The role emphasizes project management, quality assurance, and coordination among teams. Candidates should possess relevant experience and a degree in Engineering or Industrial Engineering.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3shared move
Senior Mechanical Engineer
The article outlines a job opportunity for a Senior Mechanical Engineer at ENvue, focusing on the design of disposable components and capital bedside systems. Key responsibilities include leading mechanical design, conducting analyses, and driving development cycles. Candidates should have significant experience in medical device development and a background in mechanical engineering.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3shared move
Senior Operations Manager
The article outlines the responsibilities and qualifications for a Senior Operations Manager position at ENvue. Key duties include overseeing manufacturing operations, driving lean initiatives, and managing supplier relationships. The role requires significant experience in medical device leadership and offers an opportunity to impact patient care through technology.
Read more →FEED▼ -7.4%on this news· ran to -26% by day 3shared move
Director of Clinical Education
ENvue is seeking a Director of Clinical Education to lead clinician training and develop internal curricula. The role involves managing a digital learning ecosystem and overseeing the national training center in Plymouth, MN. Candidates should have a relevant degree and clinical experience, with a focus on enteral nutrition and medical device education.
Read more →FEED▲ +5.6%on this news· ran to -17% by day 3shared move
ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
ENvue Medical has received a Notice of Allowance from the USPTO for its patent application on a feeding tube that integrates electromagnetic navigation with a distal-tip camera. This innovation aims to improve placement confidence and reduce reliance on confirmatory procedures. The patent is part of a broader family covering multiple generations of feeding tube technology, reinforcing ENvue's competitive edge in the market.
Read more →FEED▲ +11.3%on this news
More TraderTV
The article discusses the use of cookies on the TraderTV website, emphasizing their role in enhancing user experience and marketing. It also mentions the need for users to agree to the cookie policy for continued use of the site. A link to the Privacy Statement is provided for more information.
Read more →FEED▲ +11.3%on this newsshared move
New to the Street
The article discusses the use of cookies on the site, emphasizing user experience and marketing purposes. It mentions that by using the site, users agree to the cookie policy. Additionally, it directs users to read the Privacy Statement for more information.
Read more →FEED▲ +67%on this news
ENvue Medical Pushes Reusable OTC Syringes into Home Care with Distribution Deal
ENvue Medical Inc. has announced a distribution agreement with U-Deliver to market its new line of over-the-counter reusable ENFit Syringes. This product is designed to address both feeding and medication delivery needs. The agreement aims to enhance the availability of these syringes across non-acute care channels nationwide.
Read more →FEED▲ +67%on this newsshared move
ENvue Medical Launches Vibration Tech for Nasogastric Tube Comfort – A new program using vibration technology aims to alleviate discomfort from nasogastric tubes
ENvue Medical, Inc. has launched a program utilizing vibration technology from its NanoVibronix division to enhance comfort for patients with nasogastric tubes. This initiative aims to alleviate the discomfort often experienced with these tubes, which are essential in hospital settings. The program is supported by clinical research showing that micro-vibration can reduce friction at the tube-tissue interface.
Read more →FEED▲ +67%on this newsshared move
ENvue Medical launches OTC reusable syringes
ENvue Medical has launched a new line of over-the-counter ENFit syringes, which will be available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL. The company plans to distribute these syringes through online retailers, including Amazon, as well as durable medical equipment supplier channels. This initiative aims to enhance accessibility without requiring a prescription.
Read more →FEED▲ +67%on this newsshared move
Micro-Cap ENvue Medical Launches OTC Reusable Syringes for Feeding, Medication Delivery
ENvue Medical, Inc. has launched a new line of over-the-counter ENFit Syringes aimed at improving feeding and medication delivery. The syringes are designed to meet clinical needs while ensuring safety and affordability. CEO Doron Besser emphasized the importance of expanding access to standardized enteral delivery tools for both institutions and consumers.
Read more →FEED▲ +119%on this news· ran to +266% by day 1shared move
ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line
ENvue Medical has entered a distribution agreement with U-Deliver to market its ENFit syringes across non-acute care channels in the U.S. This partnership aims to enhance the availability of ENvue's products, which are designed for safe and effective enteral feeding. The syringes are available without a prescription and meet international safety standards.
Read more →FEEDDoron Besser, M.D.
Doron Besser is the CEO of ENvue Medical and NanoVibronix, where he integrates electromagnetic navigation for enteral feeding and non-invasive therapeutic devices. He has a history of leading companies to FDA clearance and market adoption, focusing on innovative medical technologies. His experience includes co-founding several medical firms and overseeing their growth and commercialization strategies.
Read more →FEEDRony Boumfeld
Rony Boumfeld has been appointed as the Chief Operating Officer at ENvue Medical, bringing over 30 years of experience from the Israel Defense Forces. His background in military intelligence and leadership roles will support the company's efforts in scaling global operations and advancing enteral navigation technology. Boumfeld is recognized for his ability to drive critical initiatives.
Read more →FEEDZenya Gorlik
Zenya Gorlik is a highly experienced software expert with over 20 years in the military and medical sectors. He has worked on various large-scale multidisciplinary projects, including geographic information systems and MRI devices. Gorlik has held significant roles at multiple companies and holds a BA in mathematics and computer science.
Read more →FEED▼ -5.2%on this news· ran to +98% by day 3shared move
Anat Hofshi, PhD
Dr. Anat Hofshi, PhD, joined ENvue Medical in 2016 to spearhead clinical activities and trials for the ENvue system's commercialization in the US. With a background in Biotechnology and Food Engineering, as well as a PhD in Physiology and Biophysics, she has a strong focus on Electrophysiology and Cardiovascular Regenerative Medicine. Her previous experience includes leadership roles in startups focused on diabetes.
Read more →FEED▼ -5.2%on this news· ran to +98% by day 3shared move
Fred Reuning
Fred Reuning is a seasoned medical device marketing executive with over 25 years of experience. He has held key positions at notable companies such as Nestle Health Sciences and Vascular Solutions. Reuning has a strong background in various medical fields and has successfully launched more than 30 products throughout his career.
Read more →FEEDENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
ENvue Medical has appointed Marc Waldman as Vice President, Commercial, to lead its U.S. commercialization strategy. Waldman brings over 35 years of experience in the medical device industry, with a proven track record in sales and strategic planning. His expertise is expected to drive revenue growth and expand ENvue's presence in hospitals.
Read more →FEEDRita Silberberg
Rita Silberberg is a seasoned financial officer with over 15 years of experience in corporate strategy and international tax planning. She has held key positions such as CFO at Gravity Creative Space and has a strong understanding of accounting regulations. Rita holds degrees in business and law, specializing in accounting and finance.
Read more →FEED▼ -6.1%on this newsshared move
Marc Waldman
Marc Waldman brings over 35 years of experience in the medical device sector, notably increasing revenue at Avanos Medical. He has held various leadership roles and is currently the Chairperson of GEDSA, focusing on improving enteral safety standards in healthcare. His career reflects a strong commitment to maternal-child health and innovation in medical devices.
Read more →FEED▼ -26.7%on this news· ran to -47% by day 3shared move
ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription
ENvue Medical has launched a line of over-the-counter ENFit Syringes aimed at improving enteral care for patients in both clinical and home settings. These syringes, available in multiple sizes, can be reused for up to seven days or 20 uses, aligning with ISO standards. The launch reflects a commitment to enhancing patient experiences and outcomes.
Read more →FEED▼ -7.6%on this news· ran to -32% by day 3shared move
ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
ENvue Medical has launched a new program aimed at reducing pain and discomfort associated with indwelling nasogastric tubes by utilizing vibration-based technology from its NanoVibronix division. This initiative is based on peer-reviewed clinical research demonstrating the effectiveness of micro-vibration technology in minimizing friction at the tube-tissue interface. Although exploratory, the program aligns with ENvue's strategy to enhance patient experience in enteral care.
Read more →FEED▼ -7.6%on this news· ran to -32% by day 3shared move
Use of surface acoustic waves to reduce pain and discomfort related to indwelling nasogastric tube
The study evaluated the NGShield device, which uses surface acoustic waves to minimize pain and discomfort associated with indwelling nasogastric tubes. Conducted on 24 healthy volunteers, the results showed that the device significantly reduced discomfort in both the nose and throat during the tube's indwelling phase. This innovation offers a promising solution to enhance patient comfort during a common medical procedure.
Read more →FEEDNanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and FEED' New ticker symbol, "FEED" will begin trading on the Nasdaq at the open of the market on
NanoVibronix, Inc. has announced a change of its corporate name to ENvue Medical, Inc., along with a new ticker symbol 'FEED' that will commence trading on Nasdaq starting December 12, 2025. This rebranding aims to highlight the company's focus on its ENvue feeding-tube placement system. Dr. Doron Besser emphasized the company's commitment to technology-driven growth and clinical excellence in its new strategy. No action is required from current shareholders due to this transition.
Read more →FEEDNanoVibronix Issues Letter to Shareholders ENvue Feeding Tube Placement System Identified as Core Growth Platform Strategic Rebranding and Name Change to Reflect Company's Focus on Multi-Billion-Dollar Enteral-Feeding Ma
NanoVibronix, Inc. announced a strategic focus on its ENvue feeding tube placement system, which it identifies as a key growth platform. The company plans to rebrand as ENvue Medical to emphasize its dedication to the enteral-feeding market. Furthermore, NanoVibronix is exploring strategic alternatives for its legacy assets and implementing initiatives to enhance revenue growth. The company's commitment to expanding its commercial footprint and clinical capabilities aims to meet the substantial opportunities in the enteral-feeding sector.
Read more →FEEDNanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules TYLER, TX
NanoVibronix, Inc. has announced a registered direct offering of $2.0 million, priced at $7.01 per share. The offering is expected to close around September 17, 2025, pending customary conditions. The proceeds will be used to enhance working capital and address certain debts. This offering is facilitated by Capital Group, LLC acting as the exclusive placement agent.
Read more →FEEDNanoVibronix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
NanoVibronix, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-10, effective on August 11, 2025. This adjustment will reduce the total outstanding shares from approximately 7.97 million to around 796,887 shares. The decision was approved by stockholders to help maintain the stock price and support the company's capital structure. The company will continue to list its shares under the NASDAQ symbol NAOV, with trading on a split-adjusted basis starting August 12, 2025.
Read more →FEEDNanoVibronix Announces CEO Transition TYLER, TEXAS
NanoVibronix, Inc. announced the retirement of CEO Brian Murphy and the immediate appointment of Doron Besser as his successor. The transition follows the strategic acquisition of ENvue Medical Holdings, which aims to enhance NanoVibronix's market reach and product portfolio. Murphy will remain with the company as a Board member to ensure governance continuity. Besser expressed confidence in leveraging recent developments to drive growth and stockholder value.
Read more →FEEDNanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants TYLER, TX
NanoVibronix, Inc. has announced a public offering of approximately 400,000 shares of its Series G Convertible Preferred Stock and associated warrants, priced at $25.00 each. The total expected gross proceeds from the offering are about $10 million, which will be utilized for debt repayment and general corporate purposes. The offering is set to close around May 19, 2025, pending customary conditions. This move indicates the company's effort to enhance its financial stability while advancing its therapeutic device technologies.
Read more →FEEDSuccessful Independent Study of the NanoVibronix UroShield Device Published in the Australian and New Zealand Continence Journal UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Q
An independent study published in The Australian and New Zealand Continence Journal has demonstrated the effectiveness of NanoVibronix's UroShield device in preventing catheter-associated urinary tract infections (CAUTIs) and blockages. The study found significant improvements for patients using UroShield, including an 86% reduction in UTI incidence and substantial decreases in other complications associated with indwelling urinary catheters. The CEO of NanoVibronix highlighted the device's ability to enhance patient care and reduce healthcare costs, marking a considerable advancement in patient management.
Read more →FEEDENVUE MEDICAL HOLDINGS, CORP. (FORMERLY ENVIZION HOLDINGS CORP.) INDEX TO FINANCIAL STATEMENTS Page Audited Consolidated Financial Statements Reports of Independent Auditors (PCAOB ID: 1281) F-2 Consolidated Balance Shee
Envue Medical Holdings Corp., formerly known as Envizion Holdings Corp., has released its audited financial statements for the years ending December 31, 2022, and 2023. The reports indicate significant financial challenges, with the company experiencing recurring losses and negative cash flows. Notably, doubts have arisen about its ability to continue operating as a going concern. These financial results demonstrate an increase in net loss and a concerning trend in current liabilities exceeding assets.
Read more →FEEDNanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield at the University of Michigan Research expected to advance to Full Study' phase in 2025 ELMSFORD, N.Y.
NanoVibronix, Inc. has announced the completion of the pilot phase of a clinical study on their UroShield device at the University of Michigan. This initial phase focused on assessing the device's potential to enhance the quality of life for nursing home residents by reducing urinary tract infections, catheter blockages, and associated pain. The company expects to advance to a full randomized control trial in 2025. This progression is seen as a significant step towards the potential commercialization of UroShield in the U.S. market, pending regulatory approval.
Read more →FEEDNanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement Extends Relationship with Ultra Pain Products, Inc for Distribution of PainShield for Five Years ELMSFO
NanoVibronix has extended its exclusive distribution agreement with Ultra Pain Products, Inc. for its PainShield device for another five years, which comes with a minimum purchase commitment of $12 million. The renewed agreement reflects confidence in UPPI's growth and innovation in the non-opioid pain management sector. Both companies emphasize their commitment to advancing patient care and supporting non-opioid treatment options. This collaboration aims to expand the reach of NanoVibronix's PainShield product within Ultra Pain Products' evolving portfolio.
Read more →FEEDASPEN 2025 Nutrition Science & Practice Conference
The article mentions the ASPEN 2025 Nutrition Science & Practice Conference but provides no specific details about the event. It primarily discusses cookie usage for user experience and marketing purposes on the website.
Read more →FEEDENvizion Medical is under a new owner, Targeting U.S. Healthcare Market Expansion
Alpha Capital Anstalt has acquired ENvizion Medical Ltd., which will now operate as ENvizion Medical Inc. The company specializes in enteral feeding tube navigation and has developed the FDA-cleared ENvue system that improves tube placement accuracy and reduces procedure times. This acquisition positions ENvizion Medical for further growth in the U.S. healthcare market.
Read more →FEEDNanoVibronix Issues Letter to Stockholders TYLER, TEXAS
NanoVibronix, Inc. issued a letter to stockholders detailing its positive financial performance in Q1 2024, marked by record revenues. The company cited improvements in product adoption, particularly within the Veterans Health System, aided by a recent GSA grant. They are optimistic about expanding their market presence, including efforts in Australia, New Zealand, and the UK. Additionally, a clinical study at the University of Michigan will evaluate the efficacy of their UroShield device, aiming for FDA clearance.
Read more →FEEDNanoVibronix Issues Letter to Stockholders ELMSFORD, N.Y.
NanoVibronix, Inc. has released a letter to stockholders detailing its achievements and goals for 2023, highlighting record revenues of $1.2 million in Q4. The company is focused on expanding its product adoption among healthcare providers, especially within Veterans Health facilities and workers' compensation plans. Recent developments include an ongoing effort to obtain full CMS approval for PainShield and an upcoming clinical trial for UroShield, aimed at evaluating its efficacy in reducing urinary tract infections. Despite challenges in regulatory approval, NanoVibronix remains optimistic about its growth prospects and market penetration.
Read more →FEEDNanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield Efforts Focused on Adding Therapeutic Functionality and Reducing Costs ELMSFORD, N.Y.
NanoVibronix, Inc. has entered into an agreement with Veranex, Inc. for the research and development of its next generation UroShield and PainShield products. This collaboration aims to enhance product functionality, improve clinician and patient satisfaction, and reduce costs. The partnership will leverage Veranex's industry expertise to ensure successful outcomes in product conception and commercialization. However, the company faces challenges, including the necessity for regulatory approvals and market acceptance of these new products.
Read more →FEEDUdi Shenig
Udi Shenig has joined the board of directors at ENvizion, bringing extensive experience in finance and corporate leadership. With 18 years as CFO and deputy CEO, he has a strong background in investment banking, M&As, and business development. His expertise includes working with public companies across various sectors, including pharmaceuticals.
Read more →FEEDEyal Gabai
The article discusses the use of cookies on the website, emphasizing their role in enhancing user experience and marketing. It informs users that by continuing to use the site, they consent to the use of cookies. A link to the Privacy Statement is provided for further information.
Read more →FEEDNanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan Gathering Additional Clinical Evidence to Support Application to FDA for Permanent Clearance ELMSFORD, N.Y.
NanoVibronix, Inc. has announced a Research Agreement with the University of Michigan to conduct a randomized control trial of its UroShield device. This study aims to provide clinical evidence to support an FDA application for permanent clearance. The research will focus on reducing urinary tract infections and pain in nursing home residents, with a pilot phase set for 20 patients followed by a larger study involving over 300 participants. The clinical trial is expected to begin in the first half of 2024.
Read more →FEEDNanoVibronix Regains Nasdaq Compliance ELMSFORD, N.Y.
NanoVibronix, Inc. has confirmed its compliance with Nasdaq's listing requirements as of November 20, 2023, ensuring the company's continued presence on The Nasdaq Capital Market. This follows the company's fulfillment of the minimum stockholders' equity requirement of $2.5 million. The matter of listing previously disclosed to the public has now been officially closed, marking a positive development for the company and its shareholders.
Read more →FEEDNanoVibronix Issues Letter to Shareholders ELMSFORD, N.Y.
NanoVibronix, Inc. has issued a letter to shareholders reviewing its third quarter 2023 performance. The company reported a revenue increase of 22% year-to-date and a 20% reduction in its operational loss. Notably, liquidity has been improved through securities sales totaling $4.2 million. The letter also highlights ongoing international market expansions and product development plans, though challenges remain, such as securing full approval from CMS.
Read more →FEEDNanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1 Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing Demand ELMSFORD, N.Y.
NanoVibronix, Inc. has announced that its UroShield actuators have been included in the NHS Drug Tariff, effective November 1, allowing for reimbursement for these devices by the NHS. The company has received a stocking order from its U.K. distribution partner, Peak Medical Limited, in anticipation of rising demand. The CEO noted an uptick in demand since the reimbursement began, indicating an optimistic outlook for increased sales and broader distribution of UroShield products. Both hospital and community clinicians can now offer UroShield through prescription, highlighting enhanced patient access.
Read more →FEEDNanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff Establishes Reimbursement for UroShield Actuators Enabling Increased Distribution to NHS Patients NHS Supply Chain
NanoVibronix, Inc. has received approval for its UroShield actuators to be included in the NHS Prescription Services' Drug Tariff, allowing for full reimbursement of costs. This crucial development enables U.K. clinicians to prescribe the UroShield devices starting November 1, 2023. The NHS Supply Chain contract for UroShield has also been extended for four years, facilitating increased distribution through Peak Medical Limited. The company plans to ramp up production to meet the expected rise in demand.
Read more →FEEDNanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting Dr. Sandra Wilks to Present Findings from University of Southampton Study in Toronto ELMSFORD, N.Y.
NanoVibronix, Inc. announced that Dr. Sandra Wilks will present positive independent testing results for UroShield at the ICS 2023 Conference in Toronto. The findings suggest that UroShield can effectively reduce catheter-associated urinary tract infections and promote a healthy urinary microbiome. This presentation aims to raise awareness among urologists and other health professionals about the benefits of UroShield, especially for long-term catheter users. The study's positive outcomes bolster the device's potential role in improving patient care and outcomes.
Read more →FEEDNanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules ELMSFORD, N.Y.
NanoVibronix, Inc. announced a private placement aimed at raising $5 million by selling 2,906,977 shares of its common stock at $1.72 per share. The offering is set to close around September 1, 2023, pending customary conditions. The funding will be utilized for corporate purposes, including development projects and sales efforts. However, the securities are not registered under the Securities Act, which may affect their trading potential.
Read more →FEEDNanoVibronix Cites Positive Results from Independent Testing of UroShield University of Southampton Study Reports Positive Outcomes in Lab and Patient Testing ELMSFORD, N.Y.
NanoVibronix, Inc. announced positive results from an independent study on its UroShield device conducted at the University of Southampton. The research indicated that UroShield effectively reduces catheter-associated urinary tract infections (CAUTIs) and catheter blockages. Approximately one-third of the study participants reported fewer catheter blockages, and most feedback was favorable regarding the device's effectiveness. The company highlights the urgent need for alternative strategies in managing infections and aims to enhance product distribution in the market.
Read more →FEEDNanoVibronix Responds to CMS' Determination for PainShield ELMSFORD, N.Y.
NanoVibronix, Inc. responded to a recent payment determination by the Centers for Medicare & Medicaid Services (CMS), which concluded that its PainShield device does not qualify for reimbursement under Medicare and Medicaid. Consequently, the company is exploring options to address CMS’s concerns and plans to resubmit an application for further review. Despite this setback, NanoVibronix emphasizes its commitment to the therapy’s potential benefits and plans to continue expanding its market presence in areas beyond Medicare and Medicaid.
Read more →FEEDNanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff Listing enables Reimbursement and Increased Distribution for NHS patients ELMSFORD, N.Y.
NanoVibronix, Inc. has applied for the inclusion of its UroShield products in the NHS Prescription Services' Drug Tariff. This move aims to facilitate reimbursement, which would allow broader distribution of the products to patients suffering from catheter-associated urinary tract infections. The company's CEO expressed optimism about the potential approval, emphasizing that increased accessibility could significantly aid patients in need. The UroShield is designed to be easily prescribed by doctors and specialist nurses, thereby streamlining treatment options.
Read more →FEEDNanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus Extension Provides for Guaranteed Purchase Minimums ELMSFORD, N.Y.
NanoVibronix, Inc. has conditionally extended its distribution agreement with Ultra Pain Products, Inc. (UPPI) for its PainShield and PainShield Plus devices. The agreement stipulates guaranteed purchase minimums until the end of 2023 and includes provisions for an immediate re-stocking order. The extension reflects UPPI's growth as the company's largest distributor since the original agreement in 2020. Additionally, NanoVibronix is optimistic about receiving reimbursement approval from the Centers for Medicare & Medicaid Services (CMS) by October 1, 2023.
Read more →FEEDNanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard PainShield MD on Exhibit at Mio-Guard Booth #1700 at the National Athletic Trainers' Association (NATA) Expo ELMSFORD, N.Y.
NanoVibronix has entered a multi-year distribution agreement with Mio-Guard for its PainShield MD product. The agreement allows Mio-Guard to exclusively sell and distribute PainShield MD to customers in the U.S., focusing on athletic team sports and sports medicine. This partnership is set against the backdrop of a growing sports medicine market, which presents significant opportunities for both companies. Mio-Guard plans to showcase the PainShield MD product prominently at the upcoming NATA Expo in Indianapolis.
Read more →FEEDNanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS) All functionalities proven to be within testing performance criteri
NanoVibronix, Inc. announced that their PainShield device received positive final results from independent lifecycle testing conducted by Carmel Labs. The testing confirmed that PainShield met all performance criteria necessary for its life expectancy. As a result, the company plans to submit these results to the Centers for Medicare and Medicaid Services to support their application for Medicare coverage, which had previously been denied due to insufficient data. The positive outcome may enhance the availability of PainShield as a non-opioid pain relief option.
Read more →FEEDNanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra Next Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness ELMSFORD, N.Y.
NanoVibronix, Inc. has announced the filing of a provisional U.S. patent application for its enhanced UroShield Ultra device, which utilizes multi-frequency surface acoustic waves to improve catheter coupling and combat Catheter Associated Urinary Tract Infections (CAUTI). This device builds on the company's existing UroShield technology and aims to improve outcomes for hospital patients. The CEO emphasized the device's potential impact on reducing hospital-acquired infections and enhancing the company’s portfolio of intellectual property assets.
Read more →FEEDNanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury Evaluators concluded that UroShield has the potential to improve quality of life and reduce healt
NanoVibronix announced positive evaluation results for its UroShield device during a recent medical conference. The independent trial, conducted by clinicians at the Royal National Orthopaedic Hospital, showed a decrease in blockages and infections for spinal cord injury patients using the device. Additionally, participants reported increased satisfaction with their catheters and potential improvements in quality of life. CEO Brian Murphy expressed optimism about the support for UroShield and its market potential.
Read more →FEEDNanoVibronix to Launch Rental Program for PainShield and UroShield Program Will Bring Greater Convenience and Accessibility to Patients ELMSFORD, N.Y.
NanoVibronix, Inc. announced the launch of a month-to-month rental program for its PainShield and UroShield products, starting March 1, 2023. This initiative aims to improve patient accessibility to these medical devices, allowing users to rent them affordably with a valid prescription. The company expects the program to be eligible for Medicare reimbursement, enhancing the financial feasibility for patients. This move aligns with NanoVibronix's goal to provide portable alternatives to traditional pain relief methods.
Read more →FEEDNanoVibronix Provides Update on Expanding Access to PainShield Receives Positive Interim Results of Lifecycle Testing Enactment of Federal NOPAIN Act' Could Be a Catalyst ELMSFORD, N.Y.
NanoVibronix, Inc. has reported positive interim results from lifecycle testing intended to support the reimbursement application for its PainShield product. The company is collaborating with The Centers for Medicare & Medicaid Services (CMS) to address previous issues regarding testing documentation. Additionally, the potential passing of the NOPAIN Act could significantly enhance the demand for PainShield and other non-opioid pain management devices by changing Medicare reimbursement policies. The company remains cautious of previous setbacks regarding reimbursement and the legislative dependency for future growth.
Read more →FEEDNANOVIBRONIX
ANNOUNCES RESULTS OF ANNUAL MEETING OF STOCKHOLDERS HELD TODAY N.Y, December 15, 2022 - NanoVibronix, Inc. (NASDAQ: NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced t
Read more →FEEDNanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules ELMSFORD, N.Y
NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq ELMSFORD, N.Y, November 29, 2022 - NanoVibronix, Inc. (NASDAQ: NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surfa
Read more →FEEDNanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus Achieves Key Milestone to Advance Commercialization ELMSFORD, N.Y.
Receives FDA 510(k) Premarket Clearance for PainShield Plus Key Milestone to Advance Commercialization N.Y., November 28, 2022 -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave
Read more →FEEDNanoVibronix Announces Interim Results of Clinical Study for UroShield Interim Results Indicate Beneficial Effects for Patients ELMSFORD, N.Y.
Announces Interim Results of Clinical Study for UroShield Results Indicate Beneficial Effects for Patients N.Y., November 16, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wav
Read more →FEEDNanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement ELMSFORD, N.Y.
Receives Extension to Satisfy Nasdaq Price Requirement N.Y., October 19, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that on October 17
Read more →FEEDNanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract New Contract is Expected to Increase Availability and Expedite Distribution of UroShield Across the United Kingdom ELMSFORD, N.Y.
UroShield Approved for Sale through NHS Internal Contract is Expected to Increase Availability and Expedite Distribution of UroShield Across the United Kingdom N.Y., September 23, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's propr
Read more →FEEDNanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
Announces Distribution of Series F Preferred Stock to Holders of its Common Stock N.Y., September 14, 2022 - NanoVibronix, Inc. (NASDAQ: NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wav
Read more →FEEDNANOVIBRONIX ANNOUNCES RECEIPT OF NASDAQ LISTING DETERMINATION
ANNOUNCES RECEIPT OF NASDAQ LISTING DETERMINATION; N.Y., September 2, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2
Read more →FEEDNANOVIBRONIX REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization ELMSFORD, N.Y.
REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization N.Y., May 17, 2022 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's propr
Read more →FEEDNanoVibronix Expands Board of Directors with Appointment of Two New Independent Directors Strengthens Board with Strategic, Corporate Governance and Financial Expertise ELMSFORD, NY /
Expands Board of Directors with Appointment of Two New Board with Strategic, Corporate Governance and Financial Expertise NY / January 13, 2022 / NanoVibronix Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield and PainShield Surface Acoustic Wave (SAW)
Read more →FEEDNANOVIBRONIX ANNOUNCES POSITIVE RESULTS FROM INDEPENENT, DOUBLE-BLIND TRIAL OF PAINSHIELD Study Finds PainShield Device is Safe and Effective in the Treatment of Tennis Elbow ELMSFORD, N.Y.
ANNOUNCES POSITIVE RESULTS FROM DOUBLE-BLIND TRIAL OF PAINSHIELD Finds PainShield Device is Safe and Effective in the Treatment of Tennis Elbow N.Y., Oct. 11, 2021 - NanoVibronix, Inc., (NASDAQ: NAOV), a healthcare device company that produces the UroShield and PainShield Sur
Read more →FEEDNANOVIBRONIX REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS; PROVIDES BUSINESS UPDATE Significantly Increasing Revenue Opportunities with Planned Launch of First OTC Product, Expanded Distribution and Additional Applicati
REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS; Increasing Revenue Opportunities with Planned Launch of First OTC Product, Expanded Distribution and Additional Applications for Regulatory Approval and Medicare Reimbursement N.Y., August 16, 2021 (Business Wire) - NanoVibronix,
Read more →FEEDNanoVibronix Provides Business Update Highlights Business Momentum with Recent Achievements; Importance of Shareholder Support for Proxy Proposal ELMSFORD, N.Y.
Provides Business Update Business Momentum with Recent Achievements; Importance of Shareholder Support for Proxy Proposal ELMSFORD, N.Y., June 3, 2021 (Business Wire) -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield and PainShield Sur
Read more →FEEDNanoVibronix Amends and Expands Distribution Agreement for Its PainShield and PainShield Plus Ultra Pain Products, Inc. to Distribute Company's Pain Management Devices to DME Market Under a Private Label in
Amends and Expands Distribution Agreement for Its PainShield and PainShield Plus Pain Products, Inc. to Distribute Company's Pain Management Devices to DME Market Under a Private Label in U.S. N.Y., December 11, 2020 (Business Wire) -- NanoVibronix, Inc., (NASDAQ: NAOV), a medi
Read more →FEEDNanoVibronix Announces $6.0 Million Private Placement ELMSFORD, N.Y.
Announces $6.0 Million Private Placement N.Y., December 2, 2020 (Business Wire) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today an
Read more →FEEDNanoVibronix Reports Third Quarter 2020 Financial Results, Provides Business Update Gaining Traction with Increased Distribution and Lower Cost Manufacturing ELMSFORD, N.Y.
Reports Third Quarter 2020 Financial Results, Traction with Increased Distribution and Lower Cost Manufacturing N.Y., November 16, 2020 (Business Wire) -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield Surf
Read more →FEEDNanoVibronix Receives Positive Nasdaq Listing Determination ELMSFORD, N.Y.
Receives Positive Nasdaq Listing Determination N.Y., Oct 8, 2020 /PRNewswire/ - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield , and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic De
Read more →FEEDE xhibit 99.1 NanoVibronix Announces $1.5 Million Bought Deal Offering ELMSFORD, N.Y.
Announces $1.5 Million Bought Deal Offering N.Y., September 22, 2020 (PR NEWSWIRE) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield , and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeu
Read more →FEEDNanoVibronix UroShield Receives U.S. Food and Drug Administration Authorization for Entry into the U.S. FDA Clears Path for Patient Access to UroShield Device for the duration of the Covid-19 pandemic; Significantly Expa
UroShield Receives U.S. Food and Drug Administration Authorization for Entry into the U.S. Clears Path for Patient Access to UroShield Device for the duration of the Covid-19 pandemic; Significantly Expands Addressable Market during this time period N.Y., September 22, 2020 (P
Read more →FEEDNanoVibronix Announces Closing of $3.4 Million Bought Deal Offering and Partial Exercise of Underwriter's Option to Purchase Additional Shares ELMSFORD, N.Y.
Announces Closing of $3.4 Million Bought Deal Offering and Partial Exercise of Underwriter's Option to Purchase Additional N.Y., August 27, 2020 (PR NEWSWIRE) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield
Read more →FEEDNanoVibronix Announces $2.5 Million Bought Deal Offering ELMSFORD, N.Y.
NanoVibronix Announces $2.5 Million Bought ELMSFORD, N.Y., August 24, 2020 (PR NEWSWIRE) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield , PainShield and WoundShield , and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Th
Read more →FEEDNanoVibronix Signs Two Year, Exclusive Distribution Agreement for PainShield Ultra Pain Products, Inc. to Distribute Products Throughout the United States Initial Order Completed ELMSFORD, N.Y.
NanoVibronix Signs Two Year, Exclusive Distribution Agreement for PainShield Ultra Pain Products, Inc. to Distribute Products Throughout the United States Initial Order Completed ELMSFORD, N.Y., July 7, 2020 (PR NEWSWIRE) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical devi
Read more →FEEDNanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary
NanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary Doctor Visits and Hospitalization During COVID-Related
Read more →FEEDAnnounces Closing of $3.2 Million Private Placement
Announces Closing of $3.2 Million Private Placement ELMSFORD, New York - June 24, 2019 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the PainShield surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low inte
Read more →FEEDNanoVibronix Announces Rescheduling of
NanoVibronix Announces Rescheduling of Annual Meeting of Stockholders ELMSFORD, New York - June 14, 2019 - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the PainShield surface acoustic wave (SAW) device, which utilizes the Company's proprietary an
Read more →FEEDAn effective Solution for the Prevention of Bacterial Load and CAUTI, Through the Application of Surface Acoustic Waves on Indwelling Catheters
An effective Solution for the Prevention of Bacterial Load and CAUTI, Through the Application of Surface Acoustic Waves on Indwelling Catheters March 11, 2019 NASDAQ : NAOV This presentation contains forward - looking statements. Forward - looking statements are based on current
Read more →FEEDNanoVibronix Provides Business Update for the Second Quarter of 2018 Revenue increases 153% for the second quarter of 2018 ELMSFORD, NY
Provides Business Update for the Second Quarter of 2018 increases 153% for the second quarter of 2018 NY - August 16, 2018 - NanoVibronix, Inc, (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW)
Read more →FEEDNanoVibronix Provides Year-End 2017 Business Update and Files 10-K ELMSFORD, NY
Provides Year-End 2017 Business Update and Files 10-K NY - April 2, 2018 - NanoVibronix, Inc, (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided a business update for the
Read more →FEEDNanoVibronix Announces Closing of $6,000,000 Public Offering ELMSFORD, NY
NanoVibronix Announces Closing of $6,000,000 Public Offering November 7, 2017 - NanoVibronix, Inc. ("NanoVibronix" or the "Company") (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave technology, today
Read more →FEEDNanoVibronix Announces Pricing of $6,000,000 Public Offering Listed on the NASDAQ Capital Market ELMSFORD, NY
NanoVibronix Announces Pricing of $6,000,000 Listed on the NASDAQ Capital Market ELMSFORD, NY - November 1, 2017 - NanoVibronix, Inc. ("NanoVibronix" or the "Company") (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surf
Read more →FEEDNanoVibronix Expands Senior Management Team and Board of Directors Appoints Industry Veterans Brian M. Murphy as Chief Executive Officer and Christopher M. Fashek as Chairman of the Board of Directors ELMSFORD, N.Y.
NanoVibronix Expands Senior Management Team and Board of Directors Appoints Industry Veterans Brian M. Murphy as Chief Executive Officer and Christopher M. Fashek as Chairman of the Board of Directors ELMSFORD, N.Y., October 20, 2016 -- NanoVibronix, Inc, (OTC: NAOV), a me
Read more →Competitive Position
How FEED ranks across every disease it competes inCompetitive Position is a premium feature
See how FEED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial